Katherine Owen - Stryker Vice President - Strategy and Investor Relations
| SYK Stock | USD 327.45 8.58 2.55% |
President
Ms. Katherine Ann Owen is Vice President Strategy and Investor Relations of the Company. She is responsible for overseeing the strategic planning and business development processes at Stryker, as well as investor relations. Prior to joining us, Ms. Owen served as a Medical Technology Analyst at Merrill Lynch. She previously served as a Medical Technology Analyst at Cowen Co.SG Cowen. She also was a Corporationrationrate Lending Analyst at State Street Bank and an Underwriter at Chubb Insurance Corporationrationration. since 2007.
| Age | 48 |
| Tenure | 17 years |
| Address | 1941 Stryker Way, Portage, MI, United States, 49002 |
| Phone | 269 385 2600 |
| Web | https://www.stryker.com |
Stryker Management Efficiency
The company has Return on Asset of 0.0687 % which means that on every $100 spent on assets, it made $0.0687 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1798 %, implying that it generated $0.1798 on every 100 dollars invested. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Stryker's Return On Capital Employed is quite stable compared to the past year. Return On Assets is expected to rise to 0.11 this year, although the value of Return On Tangible Assets will most likely fall to 0.10. At this time, Stryker's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 41.9 B this year, although the value of Non Current Liabilities Other will most likely fall to about 1.8 B.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Maulik Nanavaty | Boston Scientific Corp | ||
| John Lister | DexCom Inc | 40 | |
| Chad Phipps | Zimmer Biomet Holdings | 52 | |
| Richard Doubleday | DexCom Inc | 55 | |
| Hooman Hakami | Medtronic PLC | 48 | |
| Tony Collins | Zimmer Biomet Holdings | 48 | |
| Diogo MoreiraRato | Smith Nephew SNATS | 54 | |
| Jonathan Monson | Boston Scientific Corp | N/A | |
| Vasant Padmanabhan | Smith Nephew SNATS | 57 | |
| John Sorenson | Boston Scientific Corp | 56 | |
| Rodrigo Bianchi | Smith Nephew SNATS | 58 | |
| Deepak Nath | Abbott Laboratories | 43 | |
| Arthur Butcher | Boston Scientific Corp | 53 | |
| Michael Coyle | Medtronic PLC | 57 | |
| Coleman Lannum | Zimmer Biomet Holdings | 50 | |
| John Capek | Abbott Laboratories | 59 | |
| Andrew Lane | Abbott Laboratories | 49 | |
| Karen Burton | STERIS plc | 56 | |
| Brad Cannon | Smith Nephew SNATS | 53 | |
| Hubert Allen | Abbott Laboratories | 58 | |
| Robert Marshall | Zimmer Biomet Holdings | N/A | |
Management Performance
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0687 |
Stryker Leadership Team
Elected by the shareholders, the Stryker's board of directors comprises two types of representatives: Stryker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stryker. The board's role is to monitor Stryker's management team and ensure that shareholders' interests are well served. Stryker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stryker's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Donald Payerle, President Replacement | ||
| Lisa Tatum, Independent Director | ||
| Ronda Stryker, Independent Director | ||
| Preston Wells, Vice President - Investor Relations | ||
| Ramesh Subrahmanian, Advisor | ||
| Bradford Saar, President Medical | ||
| Spencer Stiles, Group President Orthopaedics and Spine | ||
| William Berry, Principal Accounting Officer, Vice President, Corporate Controller | ||
| Katherine Owen, Vice President - Strategy and Investor Relations | ||
| Dragana Bunjevac, Middle Europe | ||
| Giovanni Caforio, Independent Director | ||
| Jason Beach, Vice Relations | ||
| Roch Doliveux, Independent Director | ||
| William Jellison, CFO and VP | ||
| Yin Becker, Vice President - Communications, Public Affairs and Corporate Marketing | ||
| M Fink, Chief Human Resource Officer, Vice President | ||
| Dylan Crotty, President Instruments | ||
| Dean Bergy, VP and Corporate Secretary | ||
| Alan Douville, Chief VP | ||
| Glenn Boehnlein, Chief Financial Officer, Vice President | ||
| J Pierce, Group President MedSurg and Neurotechnology | ||
| Mary Brainerd, Independent Director | ||
| Srikant Datar, Independent Director | ||
| Maurice BenMayor, President Pacific | ||
| Michael Hutchinson, General Counsel | ||
| Howard Cox, Independent Director | ||
| Kathryn Fink, Chief Human Resource Officer, Vice President | ||
| Scott Bruder, Vice President Chief Medical and Scientific Officer | ||
| Andrew Silvernail, Independent Director | ||
| Fink, Vice President Global Human Resources | ||
| Sherilyn McCoy, Independent Director | ||
| Robert Cohen, CTO Replacement | ||
| Curtis Hall, Chief Legal Officer | ||
| Andrew Pierce, Group Neurotechnology | ||
| Allan Golston, Lead Independent Director | ||
| Graham Mclean, President Asia-Pacific | ||
| Stuart Silk, Middle Europe | ||
| Louise Francesconi, Independent Director | ||
| Kevin Lobo, Chairman of the Board, President, Chief Executive Officer | ||
| David Floyd, Group President of Orthopaedics | ||
| Mike Panos, North RD | ||
| Timothy Scannell, Group President of Medsurg and Neurotechnology | ||
| William Parfet, Non-Executive Independent Chairman of the Board | ||
| Robert Fletcher, Vice President Chief Legal Officer | ||
| Brian White, President Solutions | ||
| Brent Ladd, President Endoscopy | ||
| Rajeev Suri, Independent Director | ||
| Viju Menon, Group President - Global Quality and Business Operations | ||
| Lonny Carpenter, Group President - Global Quality and Operations | ||
| Bijoy Sagar, Chief Digital Technology Officer, Vice President | ||
| Bronwen Taylor, Vice President - Compliance and Risk Management | ||
| Steven Benscoter, Vice President - Human Resources |
Stryker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stryker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0687 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 138.84 B | ||||
| Shares Outstanding | 380.47 M | ||||
| Shares Owned By Insiders | 5.39 % | ||||
| Shares Owned By Institutions | 78.83 % | ||||
| Number Of Shares Shorted | 4.24 M | ||||
| Price To Earning | 63.07 X |
Stryker Investors Sentiment
The influence of Stryker's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Stryker. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Stryker's public news can be used to forecast risks associated with an investment in Stryker. The trend in average sentiment can be used to explain how an investor holding Stryker can time the market purely based on public headlines and social activities around Stryker. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Stryker's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Stryker's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Stryker's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Stryker.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Stryker in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Stryker's short interest history, or implied volatility extrapolated from Stryker options trading.
Currently Active Assets on Macroaxis
When determining whether Stryker is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stryker Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stryker Stock. Highlighted below are key reports to facilitate an investment decision about Stryker Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Stryker Stock please use our How to buy in Stryker Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Stryker Stock analysis
When running Stryker's price analysis, check to measure Stryker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stryker is operating at the current time. Most of Stryker's value examination focuses on studying past and present price action to predict the probability of Stryker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stryker's price. Additionally, you may evaluate how the addition of Stryker to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is Stryker's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stryker. If investors know Stryker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stryker listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.027 | Dividend Share 3.05 | Earnings Share 8.24 | Revenue Per Share 53.999 | Quarterly Revenue Growth 0.118 |
The market value of Stryker is measured differently than its book value, which is the value of Stryker that is recorded on the company's balance sheet. Investors also form their own opinion of Stryker's value that differs from its market value or its book value, called intrinsic value, which is Stryker's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stryker's market value can be influenced by many factors that don't directly affect Stryker's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stryker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Stryker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stryker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.